

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,643	03/20/2002	Richard Fayrer-Hosken	235.00300101	1109
26813 75	90 04/13/2006		EXAMINER	
MUETING, RAASCH & GEBHARDT, P.A.			NOLAN, PATRICK J	
	P.O. BOX 581415 MINNEAPOLIS, MN 55458		ART UNIT	PAPER NUMBER
			1644	
			DATE MAILED: 04/13/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
		10/019,643	FAYRER-HOSKEN ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Patrick J. Nolan	1644		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL CHEVER IS LONGER, FROM THE MAILING D nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. o period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailine ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
2a) <u></u>	Responsive to communication(s) filed on 14 M This action is FINAL . 2b) This Since this application is in condition for allowa closed in accordance with the practice under B	s action is non-final. nce except for formal matters, pro			
Dispositi	on of Claims				
5)	Claim(s) 4.6.12-15.17-19.21.23.27-29 and 41-4a) Of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) 4.6.12-15.17-19.21.23.27-29 and 42-Claim(s) 41 is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examine The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine The oath or declaratio	wn from consideration. 47 is/are rejected. r election requirement. er. epted or b) objected to by the Edrawing(s) be held in abeyance. See tion is required if the drawing(s) is objected.	Examiner. 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	inder 35 U.S.C. § 119	·			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
2) 🔲 Notice 3) 🔲 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 'No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	(PTO-413) te atent Application (PTO-152)		

Application/Control Number: 10/019,643 Page 2

Art Unit: 1644

1. Claims 4, 6, 12-15, 17-19, 21, 23, 27-29 and 41-47 are pending.

2. Applicant's after-final submitted 3-14-06 has been entered. The Finality of the last Office Action is hereby removed. New grounds of rejection are set forth below in a Non-Final Office Action.

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claims 4, 6, 12-15, 17-18, 21, 23, 27-29, 42 and 44-47 rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,656,488 (reference found in IDS of 2-14-03).

The '488 patent teaches the reducing or preventing of fertilization of eggs in birds by using a glycoprotein, zp3 from pigs (porcine). Wherein said zp3 glycoprotein is naturally occurring, recombinantly made and administered with or without carriers (avirulent microbes) that are dually functional (both as carriers and as immunogens) and with or without adjuvants, such as aluminum hydroxide. It is noted that claim 44 is included as carriers (avirulent microbes) that induce humoral immune responses include B cell epitopes.

The claimed invention is anticipated by the prior art teachings.

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/019,643

Art Unit: 1644

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 4, 17-19 and 43 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent 5,656,488 in view of US Patent 5,686,292.

The '488 patent has been discussed supra.

The claimed invention differs from the prior art teachings by the recitation of using adjuvant STDCM.

However, the '292 patent teaches MPL-STDCM is a known adjuvant useful to induce an immune response.

Therefore it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to be motivated to substitute the aluminum hydroxide adjuvant taught by the '488 patent with another well recognized adjuvant MPL-STDCM, since are both are known to be useful to induce immune responses to antigens.

- 7. It is noted claim 41 is objected as being dependent upon a rejected claim.
- 8. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/019,643

Art Unit: 1644

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is 571-272-0847.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at 571-272-0841.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

April 12th, 2006